Cancer Biomarker Market Research Report: By Types (Protein Biomarker, Genetic Biomarker), By Applications (Diagnostic, Prognostic, Therapeutic), By End Users (Pharmaceutical and Biotechnology Companies, Diagnostic Companies) – Forecast till 2030

Cancer Biomarker Market Overview

The cancer biomarker market is predicted to expand market value at a CAGR of 12.10% between the analysis period of 2020 to 2030. Further, the same market is estimated to generate a significant market size during the research period. In general, Cancer is considered to be a diverse disease that can occur in various tissues and organs. This different cancer condition relates to various risk factors. Here, the cancer biomarkers are known to be the molecules that are released in the presence of a tumor or a particular cancer indication in the human body. It usually indicates the presence of cancerous cells in the body, which can be either in the form of a molecule, substance, or a physical event. Generally, these molecules are found in serum, tissues, blood, urine, and other body fluids that mention a disease or any abnormal process. 

In recent past years, an alarming surge in Cancer has been evident in the worldwide population. It has been found that nearly 14 million new cases of cancer have been reported every year. As per the World Health Organisation (WHO) report, nearly22 a million new cases of cancer were reported in 2012, which is predicted to increase further by 70% over the next two decades. 

The Cancer biomarker Market Forecast report highlights that the global market is highly contributed with the support of the intended audiences. The intended audiences of the market include:

• Government and private research companies.


• Pharmaceutical companies.


• Medical research laboratories.


• Drug manufacturers and suppliers.


• Research and development (R&D) companies. 

COVID-19 Analysis

The Cancer Biomarker Market Growth has been impacted in the first half of 2020 because of the unprecedented covid-19 pandemic situation across the world. At this time, the lack of transportation, lack of workforce, disruption in the manufacturing chain and manufacturing chain has been evident. The lockdown and shutdown have made people stay inside houses which have stopped many people from getting diagnosed and treated. However, the imposed restriction has decreased the implication of testing. 

Therefore, the market players have thrown light on constituting early detection and effective preventive measures. Presently, the Cancer biomarker Market is projected to generate a larger market share in the further coming years. 

Chief Factors Existing In The Market

• Key Market Drivers

The cancer biomarker market is driven because of many factors like extensive research of cancer biomarkers, rising adoption of western lifestyles in the developing regions, improved precision and speed of diagnosis, and encouragement for the development of biomarkers by the FDA. 

Moreover, the development of highly specific drugs and rising funding relating to cancer-related research by the private and government sectors are boosting the global market growth during the research period. 

• Market Challenges

The cancer biomarker market might face bigger challenges because of the low benefit-cost ratio and high investments relating to cancer biomarkers development. 

Moreover, the strident rules and regulations of the government relating to the cancer biomarker can be one of the biggest challenges to the growth of the worldwide market during the review period. 

• Market Opportunities

The cancer biomarker market is projected to bring lucrative opportunities due to the rising investment through private and government funds in cancer-related research.

Moreover, the development of highly specific drugs relating to Cancer is projected to bring significant opportunities for the manufacturers and key players during the forecast timeframe. 

• Market Restraints

The cancer biomarker market might experience restraint because of the higher health care cost for the treatment of cancer across the globe. Cancer treatment is not affordable for many patients who are going through Cancer. Thus, the need for immediate processing and issues of reimbursement is projected to hinder the growth of the global market. 

In addition, the market might get affected because of the low success rate of clinical trials of biomarkers. 

Cumulative Evaluation of The Market

The Cancer biomarker Market Size has shown potential growth in the past few years and is further predicted to acquire a significant market size in the further coming years. 

However, the present market consists of strong market players who are working effectively to thrive on the current market performance of the market. These kinds of efforts can enhance market growth in the upcoming years. 

Market Segmentation

As per the Cancer biomarker Market Outlook report, the current market has been segmented in terms of types, end-users and applications. 

• By Types:

In terms of the type segment, the market has been classified into genetic biomarkers, protein biomarkers, and others.

All the intended audiences prefer all these types on the basis of their functionality. 

• By disease: 

The cancer biomarker market has been segmented based on Cervical Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, and other diseases.

Of these, lung cancer is predicted to old the largest Market Share during the forecast timeframe. 

• By End-User:

Depending on the end-user segment, the market has been segmented into diagnostic tool companies, pharmaceutical and biotechnology companies, clinical laboratories, healthcare big data companies, and others. 

The end-users preferred the product Cancer biomarker based on their needs and requirements. 

• By Application:

Based on the application segment, the worldwide Cancer biomarker Market has been categorized into prognostic, cancer diagnostic, and therapeutic. 

Further, the cancer diagnostic is sub-categorized into non-imaging and imaging. 

Regional Analysis

According to Cancer biomarker Market Analysis, the global market covers various regions like Europe, America, the Middle East & Africa, Asia Pacific, and others. 

Out of all, the North American market for Cancer biomarkers is anticipated to acquire the largest market share during the forecast timeframe of 2025. This region is growing due to the rising investments by the key players considering the diagnosis and detection of cancer and the high prevalence of cancer across the region. In this region, the United States is projected to lead the market because of the rising prevalence rate of Cancer, increasing investment in research and development, and major regions considering medical tourism. Moreover, this region is highly contributed because of the rising demand for personalized medicine, growing government support for the development and discovery of biomarkers, increasing biomarkers usage in drug discovery among the pharmaceutical companies, and adoption of advanced omics technologies to discover biomarkers in the region. 

Apart from all, the European market for Cancer biomarkers is showing significant market share during the analysis period due to the availability of funds for research and the rising number of clinical trials in the region. The countries like France, the U.K., and Germany are growing demand for new diagnostic tools and devices in the region, fuelling the cancer biomarker Market Value. 

Competitive Intensity Within the Industry

Many competitors are playing a significant role in thriving the performance of the market for cancer biomarkers. These market leaders are: 

• Becton Dickinson (U.S.),


• Merck & Co., Inc. (U.S.),


• Novartis AG (Switzerland),


• PerkinElmer, Inc. (U.S.),


• F. Hoffmann-La Roche AG (Switzerland), 


• Bio-Rad Laboratories (U.S.),


• Illumina Inc. (U.S.),


• Thermo Fisher Scientific Inc. (U.S.),


• Abbott Laboratories (U.S.), 


• GlaxoSmithKline plc. (U.S.),


• Bristol-Myers Squibb (U.S.), 


• Eli Lilly and Company (U.S.), 


• Pfizer Inc. (U.S.), 


• QIAGEN N.V. (U.S.).

According to the Cancer biomarker Market Trends report, these market leaders are present across the world and applying new ideas and strategies to boost the market growth in the forecast period. These market leaders are focusing on research and developmental initiatives to thrive the global market performance across the world. 

Recent Market Developments

• In December 2020, FDA gave approval to the NGS-based companion diagnostic of the prominent company Thermo Fisher Scientific (U.S.). It has aimed to provide EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.


• In April 2021, Elecsys Anti-p53 immunoassay was launched by the prominent player F. Hoffmann-La Roche Ltd. (Switzerland). It has been proposed to aid the diagnosis of different types of Cancer.

Report Overview

As per the Cancer biomarker Market report, significant market growth has been evident in the past few years and is predicted o continue the same. This report has thrown light on the regional analysis, competitive analysis, market overview, market segmentation, Covid-19 analysis, and market dynamics. 

Further, this report has highlighted the recent development in the present market to understand its marketing performance across the world. 

Key Industrial Segments

By Types:

• genetic biomarker, 


• protein biomarker, 


• others

By disease: 

• Cervical Cancer, 


• Breast Cancer, 


• Prostate Cancer, 


• Colorectal Cancer, 


• Lung Cancer, 


• other diseases

By End-User:

• diagnostic tool companies, 


• pharmaceutical and biotechnology companies, 


• clinical laboratories, 


• healthcare big data companies, 


• others

By Application:

• prognostic, 


• cancer diagnostic, 


• therapeutic